Suppression of inducible nitric oxide synthase expression induced by Toll-like receptor agonists by (E)-1-(2-(2-nitrovinyl)phenyl)pyrrolidine
- Authors
- Eom, Sang-Hoon; Gu, Gyo-Jeong; Suh, Chang Won; Koh, Kwang Oh; Kim, Dae Young; Eom, Yong-Bin; Youn, Hyung-Sun
- Issue Date
- Oct-2013
- Publisher
- Elsevier BV
- Keywords
- Toll-like receptor; Inflammation; Nuclear factor-kappa B; Inducible nitric oxide synthase; (E)-1-(2-(2-nitrovinyl)phenyl)pyrrolidine
- Citation
- International Immunopharmacology, v.17, no.2, pp 205 - 209
- Pages
- 5
- Journal Title
- International Immunopharmacology
- Volume
- 17
- Number
- 2
- Start Page
- 205
- End Page
- 209
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/13331
- DOI
- 10.1016/j.intimp.2013.06.006
- ISSN
- 1567-5769
1878-1705
- Abstract
- Toll-like receptors (TLRs) recognize many pathogen-associated molecular patterns and induce innate immunity. TLR signaling pathways induce the activation of various transcription factors, such as nuclear factor-kappa B (NF-kappa B), leading to the induction of pro-inflammatory gene products, such as inducible nitric oxide synthase (iNOS). Here, we investigated the effect of an (E)-1-(2-(2-nitrovinyl)phenyl)pyrrolidine (NVPP), previously synthesized in our laboratory, on inflammation by modulating NF-kappa B activation and iNOS expression induced by TLR agonists in murine macrophages. NVPP suppressed NF-kappa B activation and iNOS expression induced by lipopolysaccharide (TLR4 agonist), polyriboinosinic polyribocytidylic acid (TLR3 agonist), and macrophage-activating lipopeptide 2 kDa (TLR2 and TLR6 agonist). All the results suggest that NVPP is suitable for development as a new anti-inflammatory drug. (C) 2013 Elsevier B.V. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medical Sciences > Department of Biomedical Laboratory Science > 1. Journal Articles
- College of Natural Sciences > Department of Chemistry > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.